The size of the France OTC Drugs market is estimated to be USD 3.98 billion in 2020 and is projected to reach USD 4.73 billion by 2025, growing at a CAGR of 3.5% in the review period.
Pharmacies are highly prevalent throughout the country and over the counter (OTC) drugs are considered safe and are widely used by a significant population in France. People are encouraged by the government to try non-prescriptive drugs before visiting a doctor to ease the pressure on the health service. Paracetamol, aspirin, and ibuprofen are the most widely used OTC drugs in France.
Ease of access, convenience, and low cost are driving the OTC market in France. When most of the countries are considering restricting OTC sales of certain drugs, French authorities are moving in the opposite direction. Liberalizing the sales of OTC drugs is also likely to dampen the public’s expenditure on health and increase its sales. Increasing access to new channels, the cultural shift of the public towards self-medication is also fuelling the growth of the market. Online pharmacies are also being launched in France making the over the counter drugs more accessible.
However, the non-availability of reimbursements through government insurance schemes is a major setback for the OTC drug markets. The prices have also gone up in the last decade as a result of pharmacist’s monopoly on the retail segment. These along with the issues pertaining to drug substance abuse are restraining the growth of the market.
This research report is segmented & sub-segmented the France OTC Drugs Market into the following categories:
Key market participants leading France Over the Counter Drugs Market profiled in this report are Eu Yan Sang International Ltd, Bayer AG, Johnson & Johnson, GlaxoSmithKline plc, Merck Pte Ltd, Sunward Pharmaceutical Pte Ltd, Beacons Pharmaceuticals (Pte) Ltd.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Analgesics
5.1.2 Cough, Cold and Flu Products
5.1.3 Vitamins and Minerals
5.1.4 Dermatological Products
5.1.5 Gastrointestinal Products
5.1.6 Ophthalmic Products
5.1.7 Sleep Aid Products
5.1.8 Weight Loss/Diet Products
5.1.9 Others
5.2 By Formulation Type
5.2.1 Tablets
5.2.2 Liquids
5.2.3 Ointments
5.2.4 Sprays
5.3 Distribution Channels
5.3.1 Pharmacies
5.3.2 Supermarkets/Hypermarkets
5.3.3 Convenience stores
5.3.4 Others (Online Drug Stores)
6. Strategic Analysis
6.1 PESTLE analysis
6.1.1 Political
6.1.2 Economic
6.1.3 Social
6.1.4 Technological
6.1.5 Legal
6.1.6 Environmental
6.2 Porter’s Five analysis
6.2.1 Bargaining Power of Suppliers
6.2.2 Bargaining Power of Consumers
6.2.3 Threat of New Entrants
6.2.4 Threat of Substitute Products and Services
6.2.5 Competitive Rivalry within the Industry
7. Market Leaders' Analysis
7.1 GlaxoSmithKline
7.1.1 Overview
7.1.2 Product Analysis
7.1.3 Strategic Evaluation and Operations
7.1.4 Financial analysis
7.1.5 Legal issues
7.1.6 Recent Developments
7.1.7 SWOT analysis
7.1.8 Analyst View
7.2 Johnson and Johnson
7.3 Novartis
7.4 Bayer
7.5 Pfizer
7.6 Boehringer Ingelheim
7.7 Sanofi
7.8 Takeda
7.9 Yuhan Corporation
7.10 Hanmi Pharmaceuticals
7.11 Dong Wha Pharmaceuticals
8. Competitive Landscape
8.1 Market share analysis
8.2 Merger and Acquisition Analysis
8.3 Agreements, collaborations and Joint Ventures
8.4 New Product Launches
9. Expert Opinions
9.1 Market Outlook
9.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
France Over the Counter Drugs Market
Related Reports
Feb 2020
Feb 2020
Feb 2020
